ACAD – ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

ACAD

$18.28

Name : ACADIA Pharmaceuticals Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,159,313,920.00

EPSttm : 2.12

ACADIA Pharmaceuticals Inc.

$18.28

10.79%

$1.78

ACAD — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

5.33

Margin Of Safety %

Put/Call OI Ratio

0.81

EPS Next Q Diff

-0.08

EPS Last/This Y

-1.59

EPS This/Next Y

0.29

Price

18.27

Target Price

30.68

Analyst Recom

1.71

Performance Q

-37.93

Upside

302.1%

Beta

0.91

Ticker: ACAD

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	ACAD	19.41	0.56	47.58	76081
2026-10-13	ACAD	18.62	0.57	3.19	76632
2026-10-14	ACAD	19.26	0.46	11.45	71676
2026-10-15	ACAD	19.69	0.56	13.83	76945
2026-10-16	ACAD	19.13	0.56	1.36	77622
2026-10-19	ACAD	19.81	1.75	0.14	31928
2026-10-20	ACAD	20.43	1.29	0.03	36624
2026-10-21	ACAD	20.2	1.08	0.37	39625
2026-10-22	ACAD	20.3	1.04	0.40	40898
2026-10-23	ACAD	19.72	1.03	3.88	40812
2026-10-26	ACAD	19.74	1.02	19.31	40521
2026-10-27	ACAD	20.17	1.01	2.53	40415
2026-10-28	ACAD	20.31	1.01	5.30	40423
2026-10-29	ACAD	20.76	1.02	0.07	40469
2026-10-30	ACAD	20.59	1.01	1.63	40540
2026-11-02	ACAD	20.47	1.01	0.01	40533
2026-11-03	ACAD	20.58	0.85	29.27	44393
2026-11-04	ACAD	21.49	0.85	0.02	44582
2026-11-05	ACAD	21.23	0.82	0.04	45669
2026-11-06	ACAD	21.23	0.81	0.31	45708
2026-11-09	ACAD	15.94	0.81	1.58	45672
2026-11-10	ACAD	18.27	0.81	0.41	46087
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	ACAD	19.42	-56.5	198.2	0.60
2026-10-13	ACAD	18.62	-56.5	189.3	0.60
2026-10-14	ACAD	19.27	-56.7	219.4	0.60
2026-10-15	ACAD	19.69	-56.7	228.4	0.60
2026-10-16	ACAD	19.14	-56.7	194.3	0.60
2026-10-19	ACAD	19.81	-56.7	219.8	0.60
2026-10-20	ACAD	19.81	-56.7	219.8	0.60
2026-10-21	ACAD	20.44	-56.7	217.9	0.60
2026-10-22	ACAD	20.30	-56.7	207.5	0.60
2026-10-23	ACAD	19.71	-56.7	194.0	0.60
2026-10-26	ACAD	19.74	-56.5	205.6	0.60
2026-10-27	ACAD	20.17	-56.5	213.9	0.60
2026-10-28	ACAD	20.31	-56.5	208.1	0.60
2026-10-29	ACAD	20.76	-56.5	213.9	0.60
2026-10-30	ACAD	20.59	-56.5	202.3	0.60
2026-11-02	ACAD	20.47	-56.5	202.7	0.60
2026-11-03	ACAD	20.58	-56.5	205.4	0.60
2026-11-04	ACAD	21.49	-56.5	222.4	0.60
2026-11-05	ACAD	21.23	-56.5	201.1	0.60
2026-11-06	ACAD	21.23	52.5	169.6	0.60
2026-11-09	ACAD	15.48	52.5	64.7	0.60
2026-11-10	ACAD	18.27	82.5	215.2	0.73
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	ACAD	-2.52	1.51	4.87
2026-10-13	ACAD	-2.52	1.51	4.87
2026-10-14	ACAD	-2.52	1.51	4.87
2026-10-15	ACAD	-2.52	1.51	4.87
2026-10-16	ACAD	-2.52	1.51	4.87
2026-10-19	ACAD	-2.52	1.41	4.87
2026-10-20	ACAD	-2.52	1.41	4.87
2026-10-21	ACAD	-2.52	1.41	4.87
2026-10-22	ACAD	-2.52	1.41	4.87
2026-10-23	ACAD	-2.52	1.41	4.87
2026-10-26	ACAD	-2.52	1.89	4.87
2026-10-27	ACAD	-2.52	1.89	5.35
2026-10-28	ACAD	-2.52	1.89	5.35
2026-10-29	ACAD	-2.52	1.89	5.35
2026-10-30	ACAD	-2.52	1.89	5.35
2026-11-02	ACAD	-2.66	1.88	5.35
2026-11-03	ACAD	-2.66	1.88	5.35
2026-11-05	ACAD	-2.66	1.88	5.35
2026-11-06	ACAD	-2.46	1.88	5.35
2026-11-09	ACAD	-2.45	0.15	5.33
2026-11-10	ACAD	-2.45	0.15	5.33
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.31

Avg. EPS Est. Current Quarter

0.25

Avg. EPS Est. Next Quarter

0.23

Insider Transactions

-2.45

Institutional Transactions

0.15

Beta

0.91

Average Sales Estimate Current Quarter

363

Average Sales Estimate Next Quarter

350

Fair Value

28.6

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

46.3

Max Drawdown 5-Year %

-57.9

Target Price

30.68

P/E

8.68

Forward P/E

17.38

PEG

P/S

2.63

P/B

2.28

P/Free Cash Flow

38.53

EPS

2.1

Average EPS Est. Cur. Y

0.73

EPS Next Y. (Est.)

1.01

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

30.13

Relative Volume

3.07

Return on Equity vs Sector %

-0.2

Return on Equity vs Industry %

19.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.13

EBIT Estimation

215.2

◆ ACAD Healthcare

$18.28

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

12/25

Volume

0/15

Valuation

20/20

TP/AR

2/10

Options

5/10

RSI

38.4

Range 1M

31.5%

Sup Dist

21.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

16/30

Estimates

7/20

Inst/Vol

5/15

Options

5/10

EPS Yr

-67.1%

EPS NY

39%

52W%

14.1%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +77.2% upside

Quality

21/30

Valuation

24/30

Growth

13/25

Stability

9/10

LT Trend

4/5

Upside

+77.2%

Quality

MoS

57%

ACAD — P/E HistoricalBiotechnology

ACADIA Pharmaceuticals Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 796

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACAD

Latest News

—

Caricamento notizie per ACAD…

stock quote shares ACAD – ACADIA Pharmaceuticals Inc. Stock Price stock today

news today ACAD – ACADIA Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ACAD – ACADIA Pharmaceuticals Inc. yahoo finance google finance

stock history ACAD – ACADIA Pharmaceuticals Inc. invest stock market

stock prices ACAD premarket after hours

ticker ACAD fair value insiders trading

ACAD – ACADIA Pharmaceuticals Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ACAD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y